Titre : Virus de la fièvre hémorragique de Crimée-Congo

Virus de la fièvre hémorragique de Crimée-Congo : Questions médicales fréquentes

Termes MeSH sélectionnés :

Up-Regulation
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Virus de la fièvre hémorragique de Crimée-Congo : Questions médicales les plus fréquentes", "headline": "Virus de la fièvre hémorragique de Crimée-Congo : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Virus de la fièvre hémorragique de Crimée-Congo : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-02", "dateModified": "2025-02-27", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Virus de la fièvre hémorragique de Crimée-Congo" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Nairovirus", "url": "https://questionsmedicales.fr/mesh/D016855", "about": { "@type": "MedicalCondition", "name": "Nairovirus", "code": { "@type": "MedicalCode", "code": "D016855", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B04.820.480.750.565" } } }, "about": { "@type": "MedicalCondition", "name": "Virus de la fièvre hémorragique de Crimée-Congo", "alternateName": "Hemorrhagic Fever Virus, Crimean-Congo", "code": { "@type": "MedicalCode", "code": "D003225", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "None None", "url": "https://questionsmedicales.fr/author/None%20None", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Masayuki Saijo", "url": "https://questionsmedicales.fr/author/Masayuki%20Saijo", "affiliation": { "@type": "Organization", "name": "Sapporo City Public Health Office." } }, { "@type": "Person", "name": "Fei Deng", "url": "https://questionsmedicales.fr/author/Fei%20Deng", "affiliation": { "@type": "Organization", "name": "Key Laboratory of Virology and Biosafety and National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071/430207, China. df@wh.iov.cn." } }, { "@type": "Person", "name": "David W Hawman", "url": "https://questionsmedicales.fr/author/David%20W%20Hawman", "affiliation": { "@type": "Organization", "name": "Laboratory of Virology, Division of Intramural Research, NIAID, NIH, Hamilton, United States." } }, { "@type": "Person", "name": "Heinz Feldmann", "url": "https://questionsmedicales.fr/author/Heinz%20Feldmann", "affiliation": { "@type": "Organization", "name": "Laboratory of Virology, Division of Intramural Research, NIAID, NIH, Hamilton, United States." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "IL-40 is up-regulated in the synovial fluid and cartilage of osteoarthritis patients and contributes to the alteration of chondrocytes phenotype in vitro.", "datePublished": "2024-07-30", "url": "https://questionsmedicales.fr/article/39080724", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13075-024-03372-z" } }, { "@type": "ScholarlyArticle", "name": "LINC00922 decoys SIRT3 to facilitate the metastasis of colorectal cancer through up-regulation the H3K27 crotonylation of ETS1 promoter.", "datePublished": "2023-10-04", "url": "https://questionsmedicales.fr/article/37789393", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12943-023-01859-y" } }, { "@type": "ScholarlyArticle", "name": "PITX2C increases the stemness features of hepatocellular carcinoma cells by up-regulating key developmental factors in liver progenitor.", "datePublished": "2022-06-28", "url": "https://questionsmedicales.fr/article/35765089", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13046-022-02424-z" } }, { "@type": "ScholarlyArticle", "name": "MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma.", "datePublished": "2023-08-21", "url": "https://questionsmedicales.fr/article/37599362", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13046-023-02790-2" } }, { "@type": "ScholarlyArticle", "name": "Up-regulation of BOK-AS1, FAM215A and FEZF1-AS1 lncRNAs and their potency as moderate diagnostic biomarkers in gastric cancer.", "datePublished": "2023-06-23", "url": "https://questionsmedicales.fr/article/37364417", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.prp.2023.154639" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Virus", "item": "https://questionsmedicales.fr/mesh/D014780" }, { "@type": "ListItem", "position": 3, "name": "Virus à ARN", "item": "https://questionsmedicales.fr/mesh/D012328" }, { "@type": "ListItem", "position": 4, "name": "Virus à ARN de polarité négative", "item": "https://questionsmedicales.fr/mesh/D000086103" }, { "@type": "ListItem", "position": 5, "name": "Bunyaviridae", "item": "https://questionsmedicales.fr/mesh/D002043" }, { "@type": "ListItem", "position": 6, "name": "Nairovirus", "item": "https://questionsmedicales.fr/mesh/D016855" }, { "@type": "ListItem", "position": 7, "name": "Virus de la fièvre hémorragique de Crimée-Congo", "item": "https://questionsmedicales.fr/mesh/D003225" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Virus de la fièvre hémorragique de Crimée-Congo - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Virus de la fièvre hémorragique de Crimée-Congo", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-04", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Virus de la fièvre hémorragique de Crimée-Congo", "description": "Comment diagnostique-t-on l'infection par le virus CCHF ?\nQuels tests sont utilisés pour confirmer une infection CCHF ?\nQuand doit-on suspecter une infection par CCHF ?\nLes tests de laboratoire sont-ils fiables pour CCHF ?\nPeut-on diagnostiquer CCHF par des symptômes cliniques ?", "url": "https://questionsmedicales.fr/mesh/D003225?mesh_terms=Up-Regulation&page=5#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Virus de la fièvre hémorragique de Crimée-Congo", "description": "Quels sont les symptômes initiaux de CCHF ?\nY a-t-il des symptômes hémorragiques dans CCHF ?\nLes symptômes de CCHF peuvent-ils évoluer rapidement ?\nQuels signes indiquent une forme sévère de CCHF ?\nLes symptômes de CCHF sont-ils similaires à d'autres maladies ?", "url": "https://questionsmedicales.fr/mesh/D003225?mesh_terms=Up-Regulation&page=5#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Virus de la fièvre hémorragique de Crimée-Congo", "description": "Comment prévenir l'infection par CCHF ?\nLes vaccins existent-ils pour CCHF ?\nQuelles mesures de contrôle des tiques sont efficaces ?\nLes animaux domestiques peuvent-ils transmettre CCHF ?\nQuelles précautions pour les travailleurs de la santé ?", "url": "https://questionsmedicales.fr/mesh/D003225?mesh_terms=Up-Regulation&page=5#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Virus de la fièvre hémorragique de Crimée-Congo", "description": "Quel est le traitement principal pour CCHF ?\nLes antibiotiques sont-ils efficaces contre CCHF ?\nComment gérer les cas sévères de CCHF ?\nY a-t-il des traitements expérimentaux pour CCHF ?\nLe repos est-il recommandé pour les patients atteints de CCHF ?", "url": "https://questionsmedicales.fr/mesh/D003225?mesh_terms=Up-Regulation&page=5#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Virus de la fièvre hémorragique de Crimée-Congo", "description": "Quelles sont les complications possibles de CCHF ?\nCCHF peut-elle entraîner des séquelles ?\nQuel est le taux de mortalité associé à CCHF ?\nLes complications surviennent-elles rapidement ?\nComment les complications de CCHF sont-elles gérées ?", "url": "https://questionsmedicales.fr/mesh/D003225?mesh_terms=Up-Regulation&page=5#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Virus de la fièvre hémorragique de Crimée-Congo", "description": "Qui est le plus à risque de contracter CCHF ?\nLes voyageurs dans certaines régions sont-ils à risque ?\nLes personnes immunodéprimées sont-elles plus vulnérables ?\nLes agriculteurs sont-ils exposés à CCHF ?\nLes personnes en contact avec des sangs d'animaux sont-elles à risque ?", "url": "https://questionsmedicales.fr/mesh/D003225?mesh_terms=Up-Regulation&page=5#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on l'infection par le virus CCHF ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests sérologiques et PCR pour détecter le virus." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour confirmer une infection CCHF ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests ELISA et la PCR en temps réel sont couramment utilisés." } }, { "@type": "Question", "name": "Quand doit-on suspecter une infection par CCHF ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "En cas de fièvre, hémorragies et exposition à des tiques ou à des animaux infectés." } }, { "@type": "Question", "name": "Les tests de laboratoire sont-ils fiables pour CCHF ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests de laboratoire sont fiables, surtout lorsqu'ils sont effectués tôt." } }, { "@type": "Question", "name": "Peut-on diagnostiquer CCHF par des symptômes cliniques ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes cliniques sont non spécifiques; des tests sont nécessaires pour confirmation." } }, { "@type": "Question", "name": "Quels sont les symptômes initiaux de CCHF ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Fièvre, fatigue, douleurs musculaires, et maux de tête sont les premiers symptômes." } }, { "@type": "Question", "name": "Y a-t-il des symptômes hémorragiques dans CCHF ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des saignements peuvent survenir, notamment des saignements de nez et des gencives." } }, { "@type": "Question", "name": "Les symptômes de CCHF peuvent-ils évoluer rapidement ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent s'aggraver rapidement, menant à des complications graves." } }, { "@type": "Question", "name": "Quels signes indiquent une forme sévère de CCHF ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des signes de choc, des hémorragies massives et une défaillance organique sont préoccupants." } }, { "@type": "Question", "name": "Les symptômes de CCHF sont-ils similaires à d'autres maladies ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent ressembler à ceux de la dengue ou de la fièvre de Lassa, rendant le diagnostic difficile." } }, { "@type": "Question", "name": "Comment prévenir l'infection par CCHF ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les piqûres de tiques et porter des vêtements protecteurs lors de l'exposition." } }, { "@type": "Question", "name": "Les vaccins existent-ils pour CCHF ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de vaccin commercialement disponible contre CCHF." } }, { "@type": "Question", "name": "Quelles mesures de contrôle des tiques sont efficaces ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser des insecticides et maintenir l'environnement propre aide à contrôler les tiques." } }, { "@type": "Question", "name": "Les animaux domestiques peuvent-ils transmettre CCHF ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les animaux infectés peuvent transmettre le virus aux humains par contact direct." } }, { "@type": "Question", "name": "Quelles précautions pour les travailleurs de la santé ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Ils doivent porter des équipements de protection individuelle lors de la prise en charge des patients." } }, { "@type": "Question", "name": "Quel est le traitement principal pour CCHF ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de traitement antiviral spécifique; le soutien symptomatique est essentiel." } }, { "@type": "Question", "name": "Les antibiotiques sont-ils efficaces contre CCHF ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Non, les antibiotiques ne sont pas efficaces car CCHF est causée par un virus." } }, { "@type": "Question", "name": "Comment gérer les cas sévères de CCHF ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les cas sévères nécessitent une hospitalisation et un traitement de soutien intensif." } }, { "@type": "Question", "name": "Y a-t-il des traitements expérimentaux pour CCHF ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements expérimentaux, comme des anticorps monoclonaux, sont en cours d'évaluation." } }, { "@type": "Question", "name": "Le repos est-il recommandé pour les patients atteints de CCHF ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le repos est crucial pour aider le corps à combattre l'infection." } }, { "@type": "Question", "name": "Quelles sont les complications possibles de CCHF ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent le choc, l'insuffisance rénale et les hémorragies sévères." } }, { "@type": "Question", "name": "CCHF peut-elle entraîner des séquelles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains patients peuvent avoir des séquelles neurologiques ou psychologiques." } }, { "@type": "Question", "name": "Quel est le taux de mortalité associé à CCHF ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Le taux de mortalité varie de 10 à 40 % selon les épidémies et les soins reçus." } }, { "@type": "Question", "name": "Les complications surviennent-elles rapidement ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent survenir dans les jours suivant l'apparition des symptômes." } }, { "@type": "Question", "name": "Comment les complications de CCHF sont-elles gérées ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Elles nécessitent une prise en charge médicale intensive et un suivi régulier." } }, { "@type": "Question", "name": "Qui est le plus à risque de contracter CCHF ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes travaillant avec des animaux ou dans des zones endémiques sont à risque." } }, { "@type": "Question", "name": "Les voyageurs dans certaines régions sont-ils à risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les voyageurs dans des zones où CCHF est endémique courent un risque accru." } }, { "@type": "Question", "name": "Les personnes immunodéprimées sont-elles plus vulnérables ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent avoir un risque accru de développer des formes sévères de la maladie." } }, { "@type": "Question", "name": "Les agriculteurs sont-ils exposés à CCHF ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les agriculteurs sont souvent en contact avec des animaux porteurs de tiques infectées." } }, { "@type": "Question", "name": "Les personnes en contact avec des sangs d'animaux sont-elles à risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le contact avec le sang d'animaux infectés augmente le risque d'infection." } } ] } ] }

Sources (10000 au total)

IL-40 is up-regulated in the synovial fluid and cartilage of osteoarthritis patients and contributes to the alteration of chondrocytes phenotype in vitro.

IL-40 is a novel cytokine associated with autoimmune connective tissue disorders such as rheumatoid arthritis (RA) or Sjögren syndrome. We have previously shown an accumulation of IL-40 in the RA join... Immunohistochemistry was employed to detect IL-40 in paired samples of loaded and unloaded regions of osteoarthritis (OA) cartilage (n=5). Synovial fluid IL-40 was analysed by ELISA in OA (n=31) and c... IL-40 was found in chondrocytes of the superficial zone of the OA cartilage, both in loaded and unloaded explants. Additionally, only biopsies from loaded explants showed significant IL-40 positivity ... This study is the first to demonstrate the accumulation of IL-40 in OA cartilage and its up-regulation in the synovial fluid of OA patients compared to controls. In addition, extracellular IL-40 appea...

LINC00922 decoys SIRT3 to facilitate the metastasis of colorectal cancer through up-regulation the H3K27 crotonylation of ETS1 promoter.

Lysine crotonylation (Kcr) is up-regulation in colorectal cancer (CRC) tissues, while its specific contribution remains uncertain. This study aimed to elucidate the role and mechanism of crotonylation... Immunohistochemistry was employed to investigate the correlation between H3K27cr and CRC metastasis. Both in vitro and in vivo assays employing loss function or gain function approaches were conducted... Clinically, H3K27cr was upregulated in metastatic CRC tissues and positively correlated with advanced clinical stages. Functionally, knockdown of LINC00922 inhibited migration of CRC cells both in vit... Our findings uncovered a novel regulatory function of H3K27cr, regulated by LINC00922, in facilitating CRC metastasis. This discovery contributed to a deeper comprehension of the involvement of histon...

PITX2C increases the stemness features of hepatocellular carcinoma cells by up-regulating key developmental factors in liver progenitor.

Tumor cells exhibited phenotypic and molecular characteristics similar to their lineage progenitor cells. Liver developmental signaling pathways are showed to be associated with HCC development and on... To profile the dynamic gene expression during liver development, cells from an in vitro liver differentiation model and two paired hepatocellular carcinoma (HCC) samples were analyzed using deep RNA s... PITX2 was found to exhibit a similar expression pattern to specific markers of LPs. PITX2 consists of three isoforms (PITX2A/B/C). The expression of PITX2 is associated with tumor size and overall sur... PITX2C is a newly discovered transcription factor involved in hepatic differentiation and could increase HCC stemness by upregulating key transcriptional factors related to liver development....

MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma.

Medulloblastoma (MB) is the most common cerebellar malignancy during childhood. Among MB, MYC-amplified Group 3 tumors display the worst prognosis. MYC is an oncogenic transcription factor currently t... We have tested the sensitivity of MYC-driven Group 3 MB cells to a pool of transcription and splicing inhibitors that display a wide spectrum of targets. Among them, we focus on THZ531, an inhibitor o... We found that pharmacological inhibition of CDK12/13 is highly selective for MYC-high Group 3 MB cells with respect to MYC-low MB cells. We identified a subset of genes enriched in functional terms re... Our study demonstrates that CDK12/13 activity represents an exploitable vulnerability in MYC-high Group 3 MB and may pave the ground for new therapeutic approaches for this high-risk brain tumor....

Up-regulation of BOK-AS1, FAM215A and FEZF1-AS1 lncRNAs and their potency as moderate diagnostic biomarkers in gastric cancer.

Gastric cancer is the fifth most frequent cancer worldwide and the fourth leading cause of death from cancer, a complex multifactorial neoplasm. LncRNAs are regulatory RNA molecules larger than 200 nu... In this study one hundred pairs of cancerous and non-cancerous marginal tissues were gathered. Next, RNA extraction and cDNA synthesis were achieved for all of the samples. Then, the qRT-PCR was perfo... All BOK-AS1, FAM215A and FEZF1-AS1 genes showed significantly increased expression in tumor tissues compared with non-tumor tissues. The outcome of the ROC analysis demonstrated that BOK-AS1, FAM215A,... Based on the increased expression of the BOK-AS1, FAM215A and FEZF1-AS1 genes in GC patients, this study suggests that these genes may function as oncogenic factors. Furthermore, the mentioned genes c...

Combined HIF-1α and SHH Up-Regulation Is a Potential Biomarker to Predict Poor Prognosis in Postoperative Hepatocellular Carcinoma.

Hypoxia-inducible factor-1α (HIF-1α) or sonic hedgehog (SHH) is associated with hepatocellular carcinoma (HCC) progression. Hypoxia inhibits ferroptosis, which induces cancer cell death. However, the ... We detected the expression of HIF-1α and SHH in HCC. Cox regression, clinical data, and Kaplan-Meier analyses were performed. In vitro cell experiments verified the relationship between HIF-1α and SHH... HIF-1α and SHH expression levels were significantly correlated with HCC (... Combined HIF-1α and SHH upregulation is a potentially poor prognosis indicator in patients with HCC because the upregulation of SHH inhibits ferroptosis in hypoxic cancer cells....

Up-regulation of ABCG2 by MYBL2 deletion drives Chlorin e6-mediated photodynamic therapy resistance in colorectal cancer.

Photodynamic therapy (PDT) may be an effective therapeutic strategy for colorectal cancer at an early stage. However, malignant cells' resistance to photodynamic agents can lead to treatment failure. ... In the present work, a colorectal cancer cell line with a stable knockdown of MYBL2 (ShB-Myb) was constructed first. Chlorin e6 (Ce6) was utilized to induced PDT. The anti-cancer efficacy was measured... The findings indicated that the viability of ShB-Myb treated with Ce6-PDT was not decreased compared to control SW480 cells (ShNC), which were resistant to PDT. Further investigation revealed reduced ... In summary, MYBL2 absence in colorectal cancer contributes to drug resistance by activating NF-κB to up-regulate ABCG2 and thereby leading to photosensitizer Ce6 efflux. This study provides a novel th...

N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells' Properties and Lenvatinib Resistance Through WNT/β-Catenin and Hippo Signaling Pathways.

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide, but there is a deficiency of early diagnosis biomarkers and therapeutic targets. Drug resistance account... Expression of Frizzled-10 (FZD10) in liver cancer stem cells (CSCs) was identified by means of RNA sequencing and validated by means of real-time polymerase chain reaction and immunohistochemistry. In... Activation of FZD10 in liver CSCs was mediated by METTL3-dependent N6-methyladenosine methylation of FZD10 messenger RNA. Functional studies revealed that FZD10 promotes self-renewal, tumorigenicity, ... Elevated FZD10 expression promotes expansion of liver CSCs and lenvatinib resistance, indicating that FZD10 expression is a novel prognostic biomarker and therapeutic target for human HCC....